Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Overview 6 Therapeutics Development 7 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Stage of Development 7 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Therapy Area 8 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Indication 9 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Companies 12 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Universities/Institutes 14 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development 21 Galapagos NV 21 Ono Pharmaceutical Co., Ltd. 22 Ribomic Inc. 23 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles 24 GLPG-1690 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 ONO-8430506 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PAT-048 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 RBM-006 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Inhibit Autotaxin for Lung Cancer - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 X-165 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Projects 33 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Featured News & Press Releases 34 Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients 34 Sep 22, 2015: Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS 34 Feb 16, 2015: Galapagos reports positive Phase 1 results for GLPG1690 35 Jul 01, 2014: Galapagos initiates Phase 1 study with GLPG1690, triggering EU6.6 M milestone in the alliance with Janssen Pharmaceutica 35 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Review, H2 2016’, provides in depth analysis on Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted pipeline therapeutics. The report provides comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics and enlists all their major and minor projects - The report assesses Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeTable of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Overview 6 Therapeutics Development 7 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Stage of Development 7 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Therapy Area 8 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Indication 9 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Companies 12 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Products under Development by Universities/Institutes 14 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development 21 Galapagos NV 21 Ono Pharmaceutical Co., Ltd. 22 Ribomic Inc. 23 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles 24 GLPG-1690 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 ONO-8430506 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PAT-048 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 RBM-006 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Inhibit Autotaxin for Lung Cancer - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 X-165 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Projects 33 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Featured News & Press Releases 34 Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients 34 Sep 22, 2015: Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS 34 Feb 16, 2015: Galapagos reports positive Phase 1 results for GLPG1690 35 Jul 01, 2014: Galapagos initiates Phase 1 study with GLPG1690, triggering EU6.6 M milestone in the alliance with Janssen Pharmaceutica 35 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38

Galapagos NV Ono Pharmaceutical Co., Ltd. Ribomic Inc.